You have 9 free searches left this month | for more free features.

City

Condition

Prostatic Neoplasms (3)

Metastatic Castration-Resistant Prostate Cancer (2)

Metastatic Castration-resistant Prostate Cancer (mCRPC) (1)

Prostate Cancer Metastatic (1)

Overall Status

Not yet recruiting (4)

Sign in for free

Phase

phase 1 (2)

phase 3 (2)

Sponsor

Merck Sharp & Dohme LLC (4)

Collaborator

Orion Corporation, Orion Pharma (2)

Intervention

dexamethasone (4)

hydrocortisone (4)

mk-5684 (4)

fludrocortisone acetate (3)

abiraterone acetate (2)

enzalutamide (2)

fludrocortisone (1)

prednisone (1)

prednisone acetate (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (4)

Study Type

Interventional (4)

mk-5684

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial (MK-5684, Dexamethasone, Fludrocortisone)

Not yet recruiting

Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

MK-5684
+3 more

(no location specified)

Nov 13, 2023

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial (MK-5684, Dexamethasone, Fludrocortisone acetate)

Not yet recruiting

Prostatic Neoplasms
Metastatic Castration-Resistant Prostate Cancer

MK-5684
+3 more

(no location specified)

Oct 23, 2023

Prostate Cancer Metastatic Trial (MK-5684, Abiraterone acetate, Enzalutamide)

Not yet recruiting

Prostate Cancer Metastatic

MK-5684
+6 more

(no location specified)

Nov 21, 2023

Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Tumors Trial (MK-5684, Dexamethasone, Fludrocortisone

Not yet recruiting

Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms

MK-5684
+6 more

(no location specified)

Nov 21, 2023